DOUGLAS HUYNH

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Communicate with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Requested that CMS mandate state Medicaid programs to cover all PREP Act services (i.e., vaccination, testing, and treatment). Communication with the Center for Medicare and Medicaid Services regarding direct reimbursement under Medicare Program, annual payment updates, PBM transparency, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362) and The Equitable Community Access to Pharmacist Services Act (H.R. 7213).

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Other pharmacist services authorized under state law.

Communicated with Congress requesting continuation of funds for COVID-19 Uninsured Program. Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Other pharmacist services authorized under state law.

Communicated with Congress requesting continuation of funds for COVID-19 Uninsured Program. Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Other pharmacist services authorized under state law.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Other pharmacist services authorized under state law.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS.

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)

Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R.748 (CARES Act), S.3781 (Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act), S. 3780 (Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act), and S. 2723 (MEDS Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate offices, HHS and its subagencies, and DEA.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R.748 (CARES Act), S.3781 (Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act), S. 3780 (Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act), and S. 2723 (MEDS Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R.748 (CARES Act), S.3781 (Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act), S. 3780 (Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act), and S. 2723 (MEDS Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate offices, HHS and its subagencies, and DEA.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R.748 (CARES Act), S.3781 (Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act), S. 3780 (Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act), and S. 2723 (MEDS Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R.748 (CARES Act), S.3781 (Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act), S. 3780 (Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act), and S. 2723 (MEDS Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).Discussed COVID-19 response recommendations with House offices, Senate offices, and agencies.

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages.

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment.

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction and vaccinations. Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).

Discussion with the Senate on opioid addiction . Met with House and Senate to discuss issues related to drug pricing and drug shortages. Offered Support for H.R. 1499 (Protecting Consumer Access to Generic Drugs Act of 2019), H.R. 985 (Fair Access for Safe and Timely Generics Act of 2019), H.R. 2296 (FAIR Drug Pricing Act of 2019,)and S. 64 (Preserve Access to Affordable Generics and Biosimilars Act) bills that would increase transparency and competition in the prescription drug market. Offered comments on S. 1895 (Lower Health Care Costs Act).